DERM Corporate events

Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11

Published August 07, 2025 at 12:30 PM

SCOTTSDALE, Ariz., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the management team of Journey Medical will ring the closing bell at the Nasdaq MarketSite in Times Square on Monday, August 11, 2025 at 4:00 p.m. ET. Journey Medical is celebrating its 4-year anniversary as a publicly traded company on the Nasdaq Stock Market and the commercial launch of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for the treatment of rosacea.

Related Questions

Does the company plan to provide any forward‑looking statements or updates on pipeline progress during the event? Will the bell‑ringing event generate increased trading volume or short‑term price volatility? Could the timing of the event (August 11) influence the options market, particularly near‑term expirations and implied volatility? What impact might the bell‑ringing publicity have on analyst coverage and consensus rating revisions? Is there any expectation of a secondary offering, stock split, or other capital‑raising activity tied to the anniversary celebration? How will the announcement of the Emrosi™ launch affect the company's revenue forecasts and earnings guidance? How does the commercial launch of Emrosi™ compare to recent product launches by competitors in the dermatology space? Will the event include any discussion of upcoming regulatory filings or potential new indications that could impact future cash flows? Are there any anticipated changes to the share float or insider holdings surrounding the bell‑ringing ceremony? What is the market’s perception of Journey Medical’s 4‑year track record on Nasdaq, and could this milestone attract new institutional interest?